Moderna announced Tuesday that their coronavirus vaccine was 90 percent effective six months after someone received their second dose.
‘The efficacy of the vaccine starts two weeks after the second dose and based on the updated evaluated cases remains consistent with previous updates, including more than 90% against all cases of COVID-19, and greater than 95% against severe cases of COVID- 19, ” announced the company.
Modern is working to get the vaccine fully approved by the US, as it is only under emergency permits from the Food and Drug Administration.
“The Moderna team is still making significant progress with our COVID-19 vaccine,” said Moderna CEO Stéphane Bancel. “The new preclinical data on our variant-specific vaccine candidates gives us confidence that we can proactively address emerging variants.”
The study contains data from 900 cases of coronavirus, of which more than 100 are serious cases.
Along with the updated efficacy of the vaccine, Moderna is currently working on its second phase for testing in adolescents.
There are about 3,000 minors aged 12 to 17 who are fully enrolled for Moderna’s trial and the company is enrolling children from 6 months to 11 years old.
The company aims to fully enroll 6,750 healthy pediatric participants in the US and Canada.
The news about Moderna’s success comes as the FDA recommends that the administration of the Johnson & Johnson vaccine be interrupted due to blood clots.